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Significance	
Neurohormonal	Activation	in	Cardiorenal	Syndrome
Eric	Glasstetter,	BSN,	RN,	CCRN	
Introduction	 References
Nearly	five	million	people	in	the	United	
States	are	diagnosed	with	heart	failure,	
and	another	half	a	million	each	year.	
There	is	a	significant	economic	burden	as	
well,	with	nearly	$39	billion	associated	
costs	in	2010	(Coons,	McGraw,	&	Murali,	
2011).	Lifestyle	modifications	should	
include	the	elimination	of	behaviors	that	
can	further	decrease	cardiac	function.	
Modifiable	lifestyle	factors	include:	
Ø Smoking
Ø Diet
Ø Exercise	
Ø Alcohol	use	
Education	is	essential	to	reduce	the	risks	
associated	with	medications	used	in	CRS	
management,	especially	hypotension.	
Patients	should	be	educated	to:
Ø Eliminate	the	use	of	NSAID’s	which	
can	decrease	renal	function	and	
should	be	taught	to	
Ø limit	salt	substitutes	(often	low	
sodium	diets	are	implemented),	as	
the	replacements	can	be	high	it	
potassium	(O’Donovan,	2014).	
Ø Serum	potassium	and	creatinine	
levels	should	be	monitored	by	
practitioners	for	the	assessment	of	
renal	function.	At	the	initiation	of	an	
ACE-I,	renal	function	should	be	
monitored,	and	as	dosing	is	adjusted	
according	to	O’Donovan	(2014).	
The	signs	and	symptoms	associated	
with	CRS	are	similar	to	those	
experienced	in	heart	failure.	The	signs	
and	symptoms	are	the	result	of	cardiac	
and	renal	dysfunction	compounded	
together.	The		New	York	Heart	
Association	classification	scale	can	be	
used	to	describe	symptoms.	
Class	I	heart	failure	is	associated	with	
no	limitations	to	ordinary	activity	and	
can	progress	to	class	IV,	in	which	
symptoms	are	present	even	at	rest	and	
activity	only	exacerbates	discomfort.
Other	signs	and	symptoms	include:
Ø Orthopnea	
Ø Paroxysmal	Nocturnal	Dyspnea	(PND)	
Ø Reduced	Activity	Tolerance
Ø Chest	pain
Ø Edema
Ø 2	to	3	kilogram	weight	gain	per	week	
Ø Pulmonary	edema	and	crackles	
Ø Arrhythmias	
Patients	should	be	educated	on	warning	
signs	of	complications	and	what	should	
be	done	when	acute	issues	and	
complications	arise.	Quick	intervention	
can	reduce	the	likelihood	of	
exacerbations	
Cardiorenal	Syndrome	is	a	highly	
complex	pathophysiological	processes	
that	involves	several	mechanisms.	The	
RAA	system	acts	normally	as	a	
compensatory	neurohormonal
mechanism	to	maintain	GFR	and	renal	
perfusion.	In	heart	failure	however,	
chronic	activation	of	the	RAA	system	
due	to	decreased	renal	perfusion	can	
lead	the	commitment	development	of	
renal	and	cardiac	dysfunction,	deemed	
Cardiorenal	Syndrome	(Giam,	et	al.	
2016).	The	associated	
pathophysiological	process	of	CRS	
guides	therapies,	which	can	be	directly	
contradictory,	meaning	that	the	
management	of	heart	failure	can	
worsen	renal	function	and	vice	versa	
(Koniari,	et	al.,	2010).	Nursing	has	
several	implications	in	the	management	
of	CRS,	specifically	related	to	education.	
As	evidence	continues	to	emerge	
related	to	CRS,	the	management	should	
continue	to	advance,	but	at	the	current	
time,	CRS	remains	a	complex	process	
that	can	lead	to	poor	outcomes.	
Cardiac	and	renal	functioning	are	highly	
related	as	each	system	is	interdependent	
on	the	other,	and	subsequently,	
dysfunction	of	one	system	can	potentiate	
the	development	of	dysfunction	of	the	
other,	a	conditioned	referred	to	as	
Cardiorenal	Syndrome,	or	CRS.	(Scully	&	
Goldsmith,	2013).	In	CRS,	heart	failure	and	
renal	failure	exist	together.	Heart	failure	is	
the	result	of	decreased	heart	efficiency	and	
results	in	hemodynamic	and	
neurohormonal	changes	(Nicholson,	2014).	
A	decrease	in	cardiac	function	and	cause	
dysfunction	of	other	body	systems,	
including	the	renal	system,	and	at	the	same	
time,	impaired	renal	functioning	can	result	
in	increased	fluid	retention	and	increased	
systemic	vascular	resistance	and	can	prove	
to	be	detrimental	to	cardiac	function.	
According	to	Giam,	et	al.,	(2015),	 the	
prevalence	of	heart	failure	is	expected	to	
rise	nearly	46%	from	2012	to	2030	
secondary	to	the	increase	in	obesity	and	
associated	comorbid	conditions.	With	the	
prevalence	of	heart	failure	expected	to	rise	
drastically,	renal	dysfunction	associated	
with	heart	failure	is	expected	to	rise	as	
well,	with	heart	failure	being	responsible	
for	nearly	44%	of	deaths	in	patients	with	
end-stage	renal	disease	(Giam,	et	al.,	
2015).	Cardiorenal	syndrome	can	be	
divided	in	to	five	separate	sub-classes.	
A	significant	portion	of	the	
interdependence	of	cardiac	and	renal	
functioning	is	related	to	neurohormonal	
mechanisms,	most	notably	the	renin	
angiotensin	aldosterone	system,	or	RAAS.	
For	this	reason,	angiotensin	converting	
enzyme	and	inhibitors	(ACE-I)	have	become	
a	main	stay	for	the	treatment	of	heart	
failure,	however,	ACE-I’s	can	potentially	
have	detrimental	renal	effects	(Valika &	
Gheorghiade,	2012).		This	can	make	the	
management	of	CRS	difficult	for	
practitioners	and	special	considerations	
must	be	made.	Cardiorenal	Syndrome	can	
present	a	complex	challenge	for	
practitioners	and	with	new	evidence-based	
research	being	released,	there	exists	the	
possibility	for	growth	and	understanding.	
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Table	1.	Classifications	of	CRS	(House,	et	al.,	2010).	
Conclusion
Underlying	Pathophysiology
The	common	pathological	mechanism	of	CRS	is	the	chronic	activation	of	the	RAAS	
resulting	in	oxidative	stress	leading	to	impaired	cardiac	and	renal	functioning.	When	
cardiac	output	is	decreased,	hypoperfusion of	the	kidneys	and	a	decrease	in	glomerular	
filtration	rate	(GFR)	can	result.	This	decrease	in	perfusion	results	in	the	stimulation	of	
the	RAA	system,	a	normal	mechanism	of	compensation.	Activation	of	the	RAA	system	
results	in	several	changes.	First,	conversion	of	angiotensin	to	angiotensin	II	results	in	
vasoconstriction,	in	turn,	increased	systemic	vascular	resistance	and	blood	pressure.	
Second,	Aldosterone	is	stimulated	to	be	released	from	the	adrenal	cortex.	Aldosterone	
results	in	the	retention	of	fluid	and	sodium	from	the	kidneys.	The	net	effects	of	the	RAA	
system	is	increased	blood	volume	and	systemic	vascular	resistance	to	increase	renal	
perfusion.	A	negative	feedback	system	then	inhibits	the	RAA	system	once	homeostasis	is	
returned	(Klabunde,	n.d.).	
Cardiorenal	Syndrome	is	a	complex	
condition.	Normal	compensatory	
mechanisms	used	to	maintain	
homeostasis	actually	become	deleterious	
for	both	cardiac	and	renal	functioning.	
The	significance	of	the	pathophysiology	
lies	in	the	management	of	CRS.	
Ø Treatment	of	CRS	involves	choices	
that	are	contradictory	
Ø Cornerstone	of	management	is	ACE-I,	
but	use	can	worsen	renal	functioning	
as	indicated	by	elevated	serum	
creatinine	and	BUN	levels	(House,	et	
al.,	2010).	
Ø Diuretics	are	used	to	reduce	preload,	
have	been	shown	to	be	beneficial	in	
heart	failure
Ø Similar	to	ACE-I,	diuretics	can	have	
negative	renal	effects	and	further	
complicate	CRS.	
Classification	 Description	
Class	I acute	cardiac	injury	results	in	renal	
injury	
Class	II	 heart	failure	leading	to	chronic	renal	
failure	
Class	III acute	kidney	injury	resulting	in	cardiac	
injury	
Class	IV	 chronic	renal	failure	leading	to	heart	
failure	
Class	V cardiac	and	renal	dysfunction	
secondary	to	a	systemic	disease	
Signs	and	Symptoms	 Nursing	Implications
Figure	1.	Cardiorenal	Syndrome	(House,	et	al.,	2010).	
In	Cardiorenal	syndrome	however,	a	normal	compensatory	mechanism	becomes	
chronically	activated,	resulting	in	deleterious	effects	that	can	potentiate	the	failure	of	
both	cardiac	and	renal	functioning.	Chronic	activation	of	the	RAA	system	can	result	in	
hypertrophy,	inflammation,	apoptosis,	and	oxidative	stress.	Angiotensin	II	appears	to	be	
a	significant	contributor	in	CRS.	A	chronic	elevation	of	angiotensin	II	has	been	shown	to	
induce	apoptosis	in	renal	and	cardiac	cells	as	well	as	activation	of	NADPH	oxidase.	
NADPH	leads	to	increased	reactive	oxygen	species	(ROS)	which	in	turn	reduces	the	
availability	of	nitric	oxide	(vasodilating	effects	in	normal	circumstances)	and	increased	
vasoconstriction.	The	increased	levels	of	ROS	also	stimulate	the	production	of	pro-
inflammatory	mediators.	The	best	understood	mediators	are	interleukin-6	and	
transforming	growth	factor-beta,	which	contribute	to	fibrosis	in	both	the	heart	and	
kidneys.	Fibrotic	tissue	results	in	a	change	of	structure,	producing	a	change	of	function.	
Angiotensin	II	is	also	responsible	for	the	stimulation	and	release	of	aldosterone,	which	
when	chronically	activated,	can	cause	increased	collagen	formation	and	further	
increasing	fibrosis	(Giam,	et	al.,	2016).	According	to	Koniari,	et	al.	(2010),	the	cytokines	
produced	also	have	a	negative	inotropic	effect,	which	causes	a	further	reduction	in	
cardiac	output	and	renal	perfusion.	When	combined	together,	all	components	lead	to	
decreased	functioning	of	cardiac	and	renal	systems.	Other	deleterious	effects	of	chronic	
activation	of	RAA	system	includes	an	increased	preload	and	afterload,	which	can	
complicate	heart	failure	further.	
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Figure	2.	RAA	System	(Klabunde,	2014).	
